ARTV ▼ -2.6% - Artiva Biotherapeutics, Inc. $ARTV - Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026 Artiva Biotherapeutics shares fell 2.6% following the company's announcement of its planned data disclosures and development milestones for AlloNK® through the end of 2026. The update outlined the company's pipeline timeline but did not disclose any new clinical efficacy data or trial results that would typically drive a stock move in either direction. 08-SEP-2026 07:30 AM ET